Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Corsair Gaming Inc (CRSR) vs Novo Nordisk A/S (NVO) Price & Performance

Corsair Gaming IncTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Corsair Gaming Inc vs Novo Nordisk A/S — how do they compare? Corsair Gaming Inc trades at $13.64 (market cap $1.42B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 116.4× Corsair Gaming Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Corsair Gaming Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corsair Gaming Inc for 25 Days and Novo Nordisk A/S for 116 Days on average.

CRSRNVO
Market Cap
$1.42B$165.31B
Volume
1,160,93811,432,838
Sector
TechnologyHealth
52-Week High
$14.35$63.98
52-Week Low
$4.58$35.29
Typical Hold Time
25 Days116 Days
Enterprise Value
$1.41B$179.56B
Dividend Yield
—4.71%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Corsair Gaming Inc

Corsair Gaming (CRSR) trades at $13.505, down 0.63% on the day, with a bullish technical signal and recent earnings beats driving positive momentum. The stock shows improving fundamentals with a projected net income margin of 2.53% for 2026, though current valuation metrics like a P/E of 42.23 appear elevated. Recent product launches and strategic acquisitions highlight growth initiatives in the gaming and creator segments.

The outlook is cautiously optimistic, supported by analyst buy ratings and strong cash flow projections for 2026. Key risks include competitive pressures and reliance on consumer discretionary spending, but institutional interest and earnings outperformance provide a foundation for potential upside if execution continues.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.

NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CRSR
100% Buy0% Sell
Avg holding period · 25 Days
NVO
96% Buy4% Sell
Avg holding period · 116 Days

Top news

Latest headlines on both assets

About Corsair Gaming Inc

Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment

Read more on CRSR →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO →